Related Experiment Video
Updated: Jun 29, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase
Stephen Weidinger1, Kristian Reich2, Naiem Issa3,4,5,6
1Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Dermatology and Therapy
|June 27, 2026
Summary
Abrocitinib effectively treats moderate-to-severe atopic dermatitis, achieving significant skin and itch improvement. This Janus kinase inhibitor demonstrates efficacy even in patients previously treated with dupilumab.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Abrocitinib is an approved Janus kinase inhibitor for moderate-to-severe atopic dermatitis.
- Atopic dermatitis is a chronic inflammatory skin condition characterized by intense itch and skin lesions.
Purpose of the Study:
- To assess the onset and depth of response for abrocitinib in achieving EASI-90 + PP-NRS0/1.
- To compare abrocitinib's efficacy against dupilumab and placebo in different patient populations.
Main Methods:
- Post hoc analysis of JADE DARE, JADE COMPARE, and JADE EXTEND clinical trials.
- Patients received abrocitinib (100 or 200 mg) or dupilumab.
- Primary endpoint: ≥90% improvement in Eczema Area and Severity Index (EASI) and Peak Pruritus Numerical Rating Scale (PP-NRS) 0-1 (EASI-90 + PP-NRS0/1).
Main Results:
- Abrocitinib 200 mg showed higher response rates than dupilumab at week 2 in JADE DARE.
- In JADE COMPARE, abrocitinib (200 mg and 100 mg) demonstrated superior efficacy compared to dupilumab and placebo at week 16.
- Abrocitinib achieved significant results in patients with inadequate response to dupilumab in JADE EXTEND.
Conclusions:
- Abrocitinib facilitates the attainment of minimal disease activity in moderate-to-severe atopic dermatitis.
- Efficacy of abrocitinib is independent of prior dupilumab treatment.
- Abrocitinib offers a valuable therapeutic option for atopic dermatitis patients seeking rapid and substantial symptom relief.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...